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Abstract ʹ͸
Despite extraordinary efforts to profile cancer genomes, interpreting the ʹ͹
vast amount of genomic data in the light of cancer evolution remains challenging.  ʹͺ
Here we demonstrate that neutral tumor evolution results in a power-law ʹͻ
distribution of the mutant allele frequencies reported by next-generation ͵Ͳ
sequencing of tumor bulk samples. We find that the neutral power law fits with ͵ͳ
high precision 323 of 904 cancers from 14 types, selected from different cohorts. ͵ʹ
In malignancies identified as neutral, all clonal selection occurred prior to the ͵͵
onset of cancer growth and not in later-arising subclones, resulting in numerous ͵Ͷ
passenger mutations that are responsible for intra-tumor heterogeneity. ͵ͷ
Reanalyzing cancer sequencing data within the neutral framework allowed the ͵͸
measurement, in each patient, of both the in vivo mutation rate and the order and ͵͹
timing of mutations. This result provides a new way to interpret existing cancer ͵ͺ
genomic data and to discriminate between functional and non-functional intra-͵ͻ
tumor heterogeneity. ͶͲ
Introduction Ͷͳ
Unraveling the evolutionary history of a tumor is clinically valuable, as Ͷʹ
prognosis depends on the future course of the evolutionary process1,2, and Ͷ͵
therapeutic response is determined by the evolution of resistant subpopulations3. ͶͶ
In humans, the details of tumor evolution have remained largely uncharacterized Ͷͷ
as longitudinal measurements are impractical, and studies are complicated by Ͷ͸
inter-patient variation4 and intra-tumor heterogeneity (ITH)5,6. Several recent Ͷ͹
studies have begun tackling this complexity7, revealing patterns of convergent Ͷͺ
evolution8, punctuated dynamics9, and intricate interactions between cancer cell Ͷͻ
populations10. However, the lack of a rigorous theoretical framework able to ͷͲ
make predictions on existing data11 means that results from cancer genomic ͷͳ
profiling studies are often difficult to interpret. For example, how much of the ͷʹ
 ʹ
detected intra-tumor heterogeneity is actually functional is largely unknown, also ͷ͵
because a rigorous ‘null model’ of genomic heterogeneity is lacking. In particular, ͷͶ
interpreting the mutant allele frequency distribution reported by next-generation ͷͷ
sequencing (NGS) is problematic because of the absence of a formal model ͷ͸
linking tumor evolution to the observed data. Therefore, making sense to the ͷ͹
wealth of available sequencing data in cancer remains challenging.  ͷͺ
Here we show that the subclonal mutant allele frequencies of a significant ͷͻ
proportion of cancers of different types and from different cohorts precisely follow ͸Ͳ
a simple power-law distribution predicted by neutral growth. In those neutral ͸ͳ
cancers, all tumor-driving alterations responsible for cancer expansion were ͸ʹ
present in the first malignant cell and subsequent tumor evolution was effectively ͸͵
neutral. We demonstrate that under neutral growth, the fundamental parameters ͸Ͷ
describing cancer evolution that have been so far inaccessible in human tumors, ͸ͷ
such as the mutation rate and the mutational timeline, become measurable. ͸͸
Importantly, this approach allows identifying also non-neutral malignancies, in ͸͹
which ongoing clonal selection and adaption to microenvironmental niches may ͸ͺ
play a strong role during cancer growth. ͸ͻ
Results ͹Ͳ
 ͹ͳ
Neutral cancer growth ͹ʹ
Recently, we showed that colorectal cancers (CRC) often grow as a single ͹͵
expansion, populated by a large number of intermixed subclones12. ͹Ͷ
Consequently, we expect that after malignant transformation, individual ͹ͷ
subclones with distinct mutational patterns grow at similar rates, coexisting within ͹͸
the tumor for long periods of time without overtaking one another. Indeed, only a ͹͹
handful of recurrent driver alterations have been identified in CRC13, and those ͹ͺ
are reported to be ubiquitous in multi-region sampling12 and stable during cancer ͹ͻ
progression14, indicating that they all occurred in the “first” cancer cell and that ͺͲ
subsequent clonal outgrowths are relatively rare. Consequently, we hypothesized ͺͳ
that cancer evolution may often be dominated by neutral evolutionary dynamics.  ͺʹ
The dynamics of neutral evolutionary processes have been widely studied ͺ͵
in the context of molecular evolution and population genetics15-17 as well as in ͺͶ
mouse models of cancer18. However, the widely held presumption that subclone ͺͷ
dynamics in human cancers are dominated by strong selection has meant these ͺ͸
ideas have been neglected in current studies of cancer evolution.  ͺ͹
Motivated by this, here we present a theoretical model describing the ͺͺ
expected pattern of subclonal mutations within a tumor that is evolving according ͺͻ
to neutral evolutionary dynamics. The model postulates that, after the ͻͲ
accumulation of a “full house” of genomic changes that initiates tumor growth, ͻͳ
some tumors expand neutrally, generating a large number of passenger ͻʹ
mutations that are responsible for the extensive and common ITH. The ͻ͵
parameter-free model is applicable to NGS data from any solid cancer. Here we ͻͶ
present the model, and by applying it to large pre-existing cancer genomics ͻͷ
datasets, determine which tumors are consistent with neutral growth. When the ͻ͸
model applies, we measure new tumor characteristics directly from the patient’s ͻ͹
data.  ͻͺ
 ͻͻ
Model derivation ͳͲͲ
A tumor is founded by a single cell that has already acquired a significant ͳͲͳ
mutation burden4: these “pre-cancer” mutations will be borne by every cell in the ͳͲʹ
growing tumor, and so become “public” or clonal. Mutations that occur within ͳͲ͵
different cell lineages remain “private” or subclonal in an expanding malignancy ͳͲͶ
under the absence of strong selection. We focus on the latter as they contain ͳͲͷ
information on the dynamics of the cancer growth. We denote the number of ͳͲ͸
tumor cells at time t as N(t) which divide at rate Ȝ per unit time. During a cell ͳͲ͹
division, somatic mutations may occur with a probability ȝ. If we consider an ͳͲͺ
average number of ʌ chromosome sets in a cancer cell (e.g. the ploidy of the ͳͲͻ
cell), we can calculate the expected number of new mutations per time interval ͳͳͲ
as:  ͳͳͳ
 ͵
dM
dt
= µπλNȋtȌ    [1] ͳͳʹ
 ͳͳ͵
Solving this requires integrating over the growth function N(t) in some time ͳͳͶ
interval [t0,t]: ͳͳͷ
 ͳͳ͸
MȋtȌ= µπλ NȋtȌdt
tͲ
t
³      [2] ͳͳ͹
  ͳͳͺ
Since not all cell divisions may be successful in generating two surviving lineages ͳͳͻ
due to cell death or differentiation, we introduce the fraction ȕ of “effective” cell ͳʹͲ
divisions in which both resulting lineages survive. In the case of exponential ͳʹͳ
growth, the mean number of tumor cells as a function of time is therefore:  ͳʹʹ
 ͳʹ͵
NȋtȌ= eλβt       [3] ͳʹͶ
 ͳʹͷ
Substituting into equation [2] gives the explicit solution:  ͳʹ͸
 ͳʹ͹
MȋtȌ= µπβ e
λβt
−eλβtͲ( )     [4] ͳʹͺ
 ͳʹͻ
This equation describes the total number of subclonal mutations that accumulate ͳ͵Ͳ
within a growing tumor in the time interval [t0,t]. We note that for t0=0 equation [4] ͳ͵ͳ
corresponds to the Luria-Delbrück model, which describes mutation accumulation ͳ͵ʹ
in bacteria19. In our case, this equation is of limited use as none of the ͳ͵͵
parameters ȝ, Ȝ, ȕ or the age of the tumor t can be measured directly in humans. ͳ͵Ͷ
However, we do know that for a new mutation occurring at any time t, its allelic ͳ͵ͷ
frequency (the relative fraction) f must be the inverse of the number of alleles in ͳ͵͸
the population:  ͳ͵͹
  ͳ͵ͺ
f = ͳ
πNȋtȌ
=
ͳ
πeλβt
      [5] ͳ͵ͻ
 ͳͶͲ
For example, if a new mutation arises in a tumor of 100 cells, it will comprise a ͳͶͳ
fraction of 1/100. In the absence of clonal selection (or indeed significant genetic ͳͶʹ
drift), the allelic frequency of a mutation will remain constant during the ͳͶ͵
expansion, as all cells, with and without this mutation, grow at the same rate. In ͳͶͶ
the previous example, after one generation has elapsed we will have 2 cells with ͳͶͷ
that particular mutation, but a total of 200 tumor cells, again a fraction of 1/100. ͳͶ͸
This implies that in the neutral case, tumor age t and mutation frequency f are ͳͶ͹
interchangeable. For example, t0=0 in a diploid tumor (ʌ=2), corresponds to ͳͶͺ
fmax=0.5 (the expected allelic frequency of clonal variants): ͳͶͻ
 ͳͷͲ
f =
ͳ
πeλβtͲ
       [6] ͳͷͳ
 ͳͷʹ
Substituting t for f in equation [4] gives an expression for the cumulative number ͳͷ͵
of mutations in the tumor per frequency M(f):  ͳͷͶ
 ͳͷͷ
Mȋ f Ȍ= µβ
ͳ
f
−
ͳ
f
§
©¨
·
¹¸
     [7] ͳͷ͸
 ͳͷ͹
thus converging to the solution for expanding populations under neutrality ͳͷͺ
obtained using other approaches20-23. Critically, the distribution M(f) is naturally ͳͷͻ
provided by NGS data from bulk sequencing of tumor biopsies and resections, ͳ͸Ͳ
against which the model can be tested. The model predicts that mutations arising ͳ͸ͳ
during a neutral expansion of a cancer accumulate following a 1/f power-law ͳ͸ʹ
distribution. In other words, when neutral evolution occurs in a tumor, the number ͳ͸͵
 Ͷ
of mutations detected should accumulate linearly with the inverse of their ͳ͸Ͷ
frequency. The 1/f noise or pink noise is common in nature and found in several ͳ͸ͷ
physical, biological and economic systems24.  ͳ͸͸
Importantly, the coefficient ȝe=ȝ/ȕ is the mutation rate per effective cell ͳ͸͹
division, and corresponds to the easily measureable slope of M(f). This model ͳ͸ͺ
therefore provides a straightforward parameter-free method to measure the in ͳ͸ͻ
vivo mutation rate in a patient’s tumor using a single NGS sample. We note that ͳ͹Ͳ
the results do not depend on the identity of the alterations considered, since any ͳ͹ͳ
genomic alteration (mutations, copy number changes or epigenetic modifications) ͳ͹ʹ
anywhere in the genome that changes the dynamics of tumor growth (e.g. any ͳ͹͵
alteration that is clonally selected) would result in deviation from the neutral 1/f ͳ͹Ͷ
power law by causing an over- or under-representation of the alleles in that ͳ͹ͷ
clone. Hence, here we use single nucleotide variants as ‘barcodes’ to follow ͳ͹͸
clone growth. Stochastic simulations of neutral tumor growth confirm the ͳ͹͹
analytical solution in equation [7] (see Online Methods). ͳ͹ͺ
 ͳ͹ͻ
Identification of neutrality in colorectal cancer evolution ͳͺͲ
 A typical allelic frequency distribution of mutations in a tumor measured by ͳͺͳ
NGS whole-exome sequencing is shown in Figure 1A (data from ref 12). ͳͺʹ
Considering tumor purity and aneuploidy, mutations with high allelic frequency ͳͺ͵
(>0.25) are likely to be public (clonal) while all others are likely subclonal. The ͳͺͶ
same data can be represented as the cumulative distribution M(f) of subclonal ͳͺͷ
mutations as in equation [7] (Figure 1B). Remarkably, as reported by the high ͳͺ͸
goodness-of-fit measure R2, these data precisely follow the distribution predicted ͳͺ͹
by the model indicating that this tumor grew with neutral evolutionary dynamics.  ͳͺͺ
We next considered our cohort of 7 multi-sampling CRCs12 and 101 TCGA ͳͺͻ
colon adenocarcinomas13 selected for high tumor purity (70%) that underwent ͳͻͲ
whole-exome sequencing (see Online Methods). The latter were separated ͳͻͳ
between tumors characterized by chromosomal instability (CIN) versus ͳͻʹ
microsatellite instability (MSI). The power-law is remarkably well supported in ͳͻ͵
both these cohorts, with 38/108 (35.1%) of the cases reporting a high R20.98 ͳͻͶ
(Figure 1C). These results confirm that in a large proportion of colon cancers, ͳͻͷ
intra-tumor clonal dynamics are not dominated by strong selection but rather ͳͻ͸
follow neutral evolution. In particular, a larger proportion of CIN cancers evolved ͳͻ͹
neutrally (31/82, 37.8%) than MSI cancers (3/19, 15.7%) (Figure 1C), possibly ͳͻͺ
because the latter acquired so many new mutations that some are likely under ͳͻͻ
strong selection. Since M(f) is a monotonic growing function, this stringent ʹͲͲ
threshold of R2>0.98 was chosen to prevent over-calling neutrality, but we note ʹͲͳ
that we may have therefore misclassified some tumors as non-neutral due to ʹͲʹ
limited sequencing depth or low mutation burden. R2 values were independent ʹͲ͵
from the mean coverage of mutations, the total number of mutations in the ʹͲͶ
sample or the number of mutations within the model range (see Online Methods). ʹͲͷ
See Supplementary Data Set 1 (summary of TCGA data used). ʹͲ͸
 ʹͲ͹
Measurement of the mutation rate in colorectal cancer   ʹͲͺ
Estimating the per-base mutation rate ȝ per division in human ʹͲͻ
malignancies is challenging since direct measurements are not possible.  ʹͳͲ
Previous estimates critically depend on assumptions about the cell cycle time ʹͳͳ
and the growth rate Ȝ, as well as on the total mutational burden of the cancer25-27. ʹͳʹ
However, accurate measurement of all mutations within a cancer, including ʹͳ͵
heterogeneous subclonal variants, is technically unfeasible since most mutations ʹͳͶ
are present in very small numbers of cells5. With our approach it is possible to ʹͳͷ
circumvent this issue by measuring the rate of accumulation of subclonal ʹͳ͸
mutations represented by the slope of M(f). In the case of neutral evolution, this ʹͳ͹
can be done in principle within any (subclonal) frequency range, without the need ʹͳͺ
of detecting extremely rare mutations. We estimated the mutation rate in all ʹͳͻ
samples with R20.98 (Figure 1D) and found that it was more than 15-fold higher ʹʹͲ
in the MSI group (median: µe=3.65×10-6) with respect to the CIN group (median: ʹʹͳ
µe=2.31×10-7; F-test: p=2.24×10-8) and our cohort of CRCs (median: µe=2.07×10-ʹʹʹ
7), which was comprised of all but one CIN tumors12. Different mutational types ʹʹ͵
(e.g. transitions or transversions) are caused by particular mutational ʹʹͶ
processes28, and so likely occur at different rates and accordingly we found that ʹʹͷ
 ͷ
C>T mutations occurred at median µe,C>T=2.19×10-7, a rate nearly 10-fold higher ʹʹ͸
than any other type of mutation (F-test: p=3.13×10-3; Supplementary Figure 1A). ʹʹ͹
We stratified according to CIN versus MSI and found that the mutation rate of ʹʹͺ
each mutational type reflected the overall mutation rate for the group ʹʹͻ
(Supplementary Figure 1B). The variation in mutation rates within and between ʹ͵Ͳ
subgroups was remarkably in line with the variation in estimates of mutational ʹ͵ͳ
burden in colon cancer4. We note the mutation rate estimate is scaled by the ʹ͵ʹ
(unknown) effective division rate ȕ, which means for example that if only 1 in 100 ʹ͵͵
cell divisions leads to two surviving offspring (ȕ=0.01), then the mutation rate µ is ʹ͵Ͷ
100 times lower than the effective rate µe reported. Importantly, mutation rates of ʹ͵ͷ
non-neutral cases (R2<0.98) cannot be estimated, as the model does not fit the ʹ͵͸
dynamics of these tumors. ʹ͵͹
We examined the effect of copy-number changes in the model by ʹ͵ͺ
performing the analysis using only mutations in diploid regions and found highly ʹ͵ͻ
similar proportions of neutral tumors and mutation rates (see Online Methods and ʹͶͲ
Supplementary Figure 2). The validity of the variant calls was also corroborated ʹͶͳ
by the consistency of the underlying mutational signature across a range of allelic ʹͶʹ
frequencies; hence the results are unlikely to be influenced by sequencing errors ʹͶ͵
(Supplementary Figure 3).   ʹͶͶ
Frequent selection events should induce a higher number of missense and ʹͶͷ
nonsense mutations than expected by chance whereas under neutrality we ʹͶ͸
expect the same rate of silent and non-silent mutations. To test this, we ʹͶ͹
contrasted the estimated rate of synonymous mutations (unlikely to ever be ʹͶͺ
under selection) versus the rate of missense and nonsense mutations (liable to ʹͶͻ
experience selection). Although the latter are more common than the former, ʹͷͲ
after adjustment for the number of potential synonymous and non-synonymous ʹͷͳ
sites in the exome, the two rates were equivalent (Supplementary Figure 4), ʹͷʹ
consistent with neutral evolution.  ʹͷ͵
 ʹͷͶ
Neutral evolution in coding and non-coding regions ʹͷͷ
 We next tested whether the signature of neutral evolution could be found ʹͷ͸
across the entire genome, not just in coding regions. To do this, we analyzed 78 ʹͷ͹
gastric cancers from a recent study29 subjected to high depth whole-genome ʹͷͺ
sequencing. The large number of mutations detected by WGS accumulated ʹͷͻ
precisely as predicted by the model (example in Figure 2A,B), revealing neutral ʹ͸Ͳ
evolution in 60/78 (76.9%) cases (Figure 2C). A smaller proportion of MSI tumors ʹ͸ͳ
were neutral (3/10, 30%) than microsatellite stable (MSS) tumors (57/68, 83.8%) ʹ͸ʹ
consistent with the observation in CRC. A tumor was consistently classified as ʹ͸͵
neutral independently of whether all SNVs or only non-coding SNVs were used to ʹ͸Ͷ
perform the classification (Figure 2C, Venn diagram), whereas due to the limited ʹ͸ͷ
number of mutations available in the exome alone, fewer tumors were identified ʹ͸͸
as neutral.  Importantly, every case was verified as neutral by at least two ʹ͸͹
different variant sets. These results confirm that neutral evolution can be robustly ʹ͸ͺ
assessed from mutations anywhere in the genome.  ʹ͸ͻ
Mutation rate analysis of the neutrally evolved gastric cancers revealed ʹ͹Ͳ
that MSI cancers had a more than 4-fold higher mutation rate (µe=3.30×10-6) with ʹ͹ͳ
respect to MSS (µe=7.82×10-7; F-test: p=1.35×10-4). Results were robust to copy ʹ͹ʹ
number changes when the analysis was performed only using variants in diploid ʹ͹͵
regions (Supplementary Figure 5). The mutational signature of the variant calls ʹ͹Ͷ
for this cohort was also consistent across the frequency spectrum ʹ͹ͷ
(Supplementary Figure 6). Synonymous versus nonsynonymous mutation rates ʹ͹͸
were also not consistent with frequent on-going selection (Supplementary Figure ʹ͹͹
7). See Supplementary Data Set 2 (summary of Wang et al. data used). ʹ͹ͺ
 ʹ͹ͻ
Neutral evolution across cancer types ʹͺͲ
We then applied our neutral model to a large pan-cancer cohort of 819 ʹͺͳ
exome-sequenced cancers from 14 tumor types from the TCGA consortium ʹͺʹ
(which included the 101 colon cancers previously examined). All of these ʹͺ͵
samples had been pre-selected for high tumor purity (70%). The fit of the model ʹͺͶ
was remarkably good across types (Figure 3A) with 259/819 (31.6%) cases ʹͺͷ
showing R20.98. We found that neutral evolution was more prominent in some ʹͺ͸
tumor types, such as stomach (validating the WGS analysis), lung, bladder, ʹͺ͹
 ͸
cervical, and colon. Others showed a consistently poorer fit, indicating that the ʹͺͺ
clonal dynamics in these malignancies were typically not neutral, such as renal, ʹͺͻ
melanoma, pancreatic, thyroid, and glioblastoma. Consistent with these results, ʹͻͲ
“non-neutral” renal carcinoma has been shown to display convergent evolution in ʹͻͳ
spatially disparate tumor regions driven by strong selective forces8, whereas the ʹͻʹ
same phenomenon was not found in more “neutral” lung cancer30,31. Other types ʹͻ͵
displayed mixed dynamics, with some cases that were characterized by neutral ʹͻͶ
evolution and some that were not. We note that a proportion of melanoma ʹͻͷ
samples in this cohort are derived from regional metastases and not primary ʹͻ͸
lesions, and this could potentially explain the lack of neutral dynamics observed. ʹͻ͹
Mutation rate analysis on the neutral cases showed differences of more ʹͻͺ
than an order of magnitude between types (Figure 3B).  The highest mutation ʹͻͻ
rates were observed in lung adenocarcinoma (median µe=6.79×10-7) and in lung ͵ͲͲ
squamous cell carcinoma (median µe=5.61×10-7) and the lowest rates in low ͵Ͳͳ
grade glioma (median µe=9.22×10-8) and in prostate (median µe=1.04×10-7). We ͵Ͳʹ
stratified the mutation rates into different mutational types (Supplementary Figure ͵Ͳ͵
8) and found that C>A mutations occurred at a significantly higher rate in lung ͵ͲͶ
cancers, consistent with their causation by tobacco smoke28. C>T mutation rates ͵Ͳͷ
were most consistent across cancer types, likely because of their association ͵Ͳ͸
with normal replicative errors, as opposed to being caused by a particular ͵Ͳ͹
stochastically-arising defect in DNA replication or repair28. ͵Ͳͺ
These results demonstrate that within-tumor clonal dynamics can be ͵Ͳͻ
neutral, and the classification of tumors based on neutral versus non-neutral ͵ͳͲ
growth dynamics leads to new measurements of fundamental tumor biology. See ͵ͳͳ
See Supplementary Data Set 1 (summary of TCGA data used). ͵ͳʹ
 ͵ͳ͵
In silico validation of the neutral model ͵ͳͶ
To assess the different inherent sources of noise in NGS data (normal ͵ͳͷ
contamination, limited sequencing depth, tumor sampling), we designed a ͵ͳ͸
stochastic simulation of neutral growth that produced synthetic NGS data from ͵ͳ͹
bulk samples (see Online Methods). The simulations produced realistic synthetic ͵ͳͺ
NGS data (Supplementary Figure 9) with minimal assumptions and under a ͵ͳͻ
range of different scenarios for tumor growth dynamics (variable low mutation ͵ʹͲ
rate, variable number of clonal mutations) and sources of assay noise (normal ͵ʹͳ
contamination in the sample, sequencing depth, detection limit). For each of ͵ʹʹ
these potentially confounding factors, we were able to fit our neutral model to the ͵ʹ͵
synthetic NGS data and accurately recover both the underlying neutral dynamics ͵ʹͶ
and mutation rate (Supplementary Figure 10). We also validated the prediction ͵ʹͷ
that M(f) would deviate from the neutral power law in the presence of emerging ͵ʹ͸
subclones with a higher fitness advantage (Supplementary Figure 11A,B), as well ͵ʹ͹
as in the case of a mixture of subclones (as observed in ref. 32) emerging either ͵ʹͺ
by means of clonal expansions triggered by selection, or by segregating ͵ʹͻ
microenvironmental niches (Supplementary Figure 11C-F). Variation of mutation ͵͵Ͳ
rate between subclones also causes a deviation from neutrality (Supplementary ͵͵ͳ
Figure 11G,H). These results confirm the reliability of the conservatively high R2 ͵͵ʹ
threshold used to call neutrality. ͵͵͵
 ͵͵Ͷ
Mutational timelines ͵͵ͷ
Under neutral evolution, it is possible to estimate the size of the tumor ͵͵͸
when a mutation with frequency f arose from equation [5]: ͵͵͹
 ͵͵ͺ
NȋtȌ= ͳ
π f
      [8] ͵͵ͻ
 ͵ͶͲ
Figure 4A,B shows the decomposition of the mutational timeline for two ͵Ͷͳ
illustrative cases: sample TB from12 and sample TCGA-AA-3712 from13. Previous ͵Ͷʹ
estimates of mutational timelines relied on cross-sectional data33-36 that are ͵Ͷ͵
compromised by the extensive heterogeneity, whereas multi-region profiling ͵ͶͶ
approaches are instead more accurate but expensive and laborious8,37,38. Using ͵Ͷͷ
our formal model of cancer evolution this timeline information becomes ͵Ͷ͸
accessible from routinely available genomic data. We found that classical CRC ͵Ͷ͹
driver alterations, such as in the APC, KRAS and TP53 genes, were indeed ͵Ͷͺ
 ͹
present in the first malignant cell (likely because they accumulated during ͵Ͷͻ
previous neoplastic stages). This confirms what we previously reported using ͵ͷͲ
single-gland mutational profiling where all these drivers, when present, were ͵ͷͳ
found in all glands12. However, we also found that when we considered a more ͵ͷʹ
extended list of putative drivers, many occurred during the neutral phase of tumor ͵ͷ͵
growth, suggesting that the selective advantage conferred by a putative driver ͵ͷͶ
alteration may be context-dependent, as demonstrated in a p53 murine model39. ͵ͷͷ
Discussion ͵ͷ͸
 Understanding the evolutionary dynamics of subclones within human ͵ͷ͹
cancers is challenging because longitudinal observations are unfeasible and the ͵ͷͺ
genetic landscape of cancer is highly dynamic, leading to genomic data that are ͵ͷͻ
hard to interpret40. In particular, complex non-linear evolutionary trajectories have ͵͸Ͳ
been observed, such as punctuated evolution and karyotypic chaos9,40,41. Here ͵͸ͳ
we have presented a formal law that predicts mutational patterns routinely ͵͸ʹ
reported in NGS of bulk cancer specimens. Our analysis of large independent ͵͸͵
cohorts using this framework shows that cancer growth is often dominated by ͵͸Ͷ
neutral evolutionary dynamics, an observation that is consistent across 14 cancer ͵͸ͷ
types. Under neutrality, the clonal structure of a tumor is expected to have a ͵͸͸
fractal topology characterized by self-similarity (Figure 5). As the tumor grows, a ͵͸͹
large number of cell lineages are generated and therefore ITH rapidly increases ͵͸ͺ
while the allele frequency of the new heterogeneous mutations quickly decreases ͵͸ͻ
due to the expansion. This implies that sampling in different parts of the tree ͵͹Ͳ
leads to the detection of distinct mutations which all show the same 1/f ͵͹ͳ
distribution. Clonal mutations found in a sample (not considered in the model) ͵͹ʹ
belong to the most recent common ancestor in the tree.  ͵͹͵
We note that some cancers were dominated by neutral evolution whereas ͵͹Ͷ
others were not. In non-neutral tumors, strong selection, microenvironmental ͵͹ͷ
constrains and non-cell autonomous effects42 may play a key role. Importantly, ͵͹͸
our formalization represents the ‘null model’ of cancer intra-clone heterogeneity ͵͹͹
that can be used to identify those cases in which complex non-neutral dynamics ͵͹ͺ
occur, and to discriminate between functional and non-functional intra-tumor ͵͹ͻ
heterogeneity. Furthermore, we speculate that neutral evolutionary dynamics ͵ͺͲ
may be favored by the cellular architecture of the tumor (e.g. glandular structures ͵ͺͳ
that limit the effects of selection) and/or the anatomical location of the malignancy ͵ͺʹ
(e.g. growing in a lumen versus growing in a highly confined space), as well as ͵ͺ͵
the presence of potentially selective microenvironmental features of the tumor ͵ͺͶ
such as hypoxic regions. Despite the evidence for lack of natural selection during ͵ͺͷ
malignant growth, eventual treatment is likely to “change the rules of the game” ͵ͺ͸
and strongly select for treatment resistant clones. The same may happen in the ͵ͺ͹
context of the purported evolutionary bottleneck preceding metastatic ͵ͺͺ
dissemination, wherein treatment-resistance driver alterations that were not ͵ͺͻ
under selection during growth may expand due to new selective pressures ͵ͻͲ
introduced by therapy. Importantly, this reasoning highlights how ‘drivers’ can ͵ͻͳ
only defined within a context, and so the same ‘driver’ alteration can be neutral in ͵ͻʹ
a certain microenvironmental context (e.g. absence of treatment), and not neutral ͵ͻ͵
in another (e.g. during treatment). Moreover, we predict that if a tumor is ͵ͻͶ
characterized by different microenvironmental niches but still presents as neutral, ͵ͻͷ
it is likely that adaptation will be driven by cancer cell plasticity, rather than clonal ͵ͻ͸
selection. Cell plasticity is hard to study in cancer because it implies a change in ͵ͻ͹
the cell phenotype that is not caused by any inheritable change (genomic or ͵ͻͺ
epigenomic). This means that this phenomenon has been so far largely ͵ͻͻ
neglected in cancer. As neutrality can be used as the ‘null model’ with which to ͶͲͲ
identify clonal selection, this facilitates the study of adaptation through plasticity ͶͲͳ
directly in human malignancies. ͶͲʹ
Furthermore, it is important to note that due to the intrinsic sub-clonal ͶͲ͵
detection limits of sequencing technologies, it is possible to explore only the early ͶͲͶ
expansion of cancer clones (Figure 5) and hence the dynamics of small clones ͶͲͷ
may differ from the tumor bulk as a whole. ͶͲ͸
Importantly, the realization that the within-tumor clonal dynamics are ͶͲ͹
neutral means that the in vivo mutation rate per division and the mutational ͶͲͺ
 ͺ
timeline, factors that play a key role in cancer evolution, progression and ͶͲͻ
treatment resistance can be inferred without the need to assume cell division ͶͳͲ
rates. These measurements can be performed in a patient-specific manner and Ͷͳͳ
so may be useful for prognostication and the personalization of therapy. Ͷͳʹ
Recognizing that the growth of a neoplasm is dominated by neutral clonal Ͷͳ͵
dynamics provides an analytically tractable and rigorous method to study cancer ͶͳͶ
evolution and gain clinically relevant insight from commonly available genomic Ͷͳͷ
data.  Ͷͳ͸
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Figure Legends ͷͶͷ
ͷͶ͸
Figure 1. Neutral evolution is common in colon cancer and allows the ͷͶ͹
measurement of mutation rates in each tumor. (A) The output of NGS data, ͷͶͺ
such as whole-exome sequencing, can be summarized as a histogram of mutant ͷͶͻ
allele frequencies, here for sample TB. Considering purity and ploidy, mutations ͷͷͲ
with relatively high frequency (>0.25) are likely to be clonal (public), whereas low ͷͷͳ
frequency mutations capture the tumor subclonal architecture. (B) The same data ͷͷʹ
can be represented as the cumulative distribution M(f) of subclonal mutations. ͷͷ͵
This was found to be linear with 1/f, precisely as predicted by our neutral model. ͷͷͶ
(C) R2 goodness of fit of our CRC cohort (n=7) and the TCGA colon cancer ͷͷͷ
cohort (n=101) grouped by CIN versus MSI confirmed that neutral evolution is ͷͷ͸
common (38/108, 35.1% with R20.98). (D) Measurements of the mutation rate ͷͷ͹
showed that the CIN groups had median mutation rate of µe=2.31×10-7, whereas ͷͷͺ
MSI tumors reported a 15-fold higher rate (median: µe=3.65×10-6, F-test: ͷͷͻ
p=2.24×10-8), as predicted due to their DNA mismatch repair deficiency.  ͷ͸Ͳ
 ͷ͸ͳ
Figure 2. Neutral evolution across the whole-genome of gastric cancers. (A) ͷ͸ʹ
Large number of coding and non-coding mutations can be identified using WGS. ͷ͸͵
(B) All detected mutations precisely accumulate as 1/f following the neutral model ͷ͸Ͷ
in this example. (C) Neutral evolution is very common in gastric cancer, with ͷ͸ͷ
60/78 (76.9%) samples showing goodness of fit of the neutral model R20.98. ͷ͸͸
This was consistent using all, exonic or non-coding subclonal mutations. The ͷ͸͹
same tumors were identified as neutral by all three methods, although limitations ͷ͸ͺ
in detecting neutrality were present when considering exonic mutations due to ͷ͸ͻ
the limited number of variants. (D) Mutation rates were more than 4 times higher ͷ͹Ͳ
in MSI (µe=3.30×10-6) versus MSS (µe=7.82×10-7; F-test: p=1.35×10-4) cancers, ͷ͹ͳ
consistently with the underlying biology. ͷ͹ʹ
 ͷ͹͵
Figure 3. Neutral evolution and mutation rates across cancer types. (A) R2 ͷ͹Ͷ
values from 819 cancers of 14 different types supported neutral evolution in a ͷ͹ͷ
large proportion of cases (259/819, 31.6% of R20.98) and across different ͷ͹͸
cancer types, particularly in stomach (validating the WGS analysis), lung, ͷ͹͹
bladder, cervical and colon. On the contrary, renal, melanoma, pancreatic, ͷ͹ͺ
thyroid, and glioblastoma were characterized by non-neutral evolution. The other ͷ͹ͻ
types displayed a mixed dynamics. (B) The highest mutation rates were found in ͷͺͲ
lung cancer and melanoma. Lower rates were found in thyroid, low grade glioma ͷͺͳ
and prostate. ͷͺʹ
 ͷͺ͵
 ͳͳ
Figure 4. Reconstruction of the mutational timeline in each patient. The ͷͺͶ
frequency of a mutation within the tumor predicts the size of the tumor when the ͷͺͷ
mutation occurred. (A,B) The deconvolution of the mutational timeline is ͷͺ͸
illustrated for samples TB and TCGA-AA-3712 respectively. Whereas established ͷͺ͹
CRC drivers (APC, KRAS, TP53) were found to be present from the first ͷͺͺ
malignant cell, several recurrent putative drivers not yet validated were mutated ͷͺͻ
after malignant seeding, despite the underlying neutral dynamics. This suggests ͷͻͲ
that some of these candidate alterations may not be fundamental drivers of ͷͻͳ
growth in all cases. Confidence intervals are calculated using a binomial test on ͷͻʹ
the number of variant reads versus the depth of coverage for each mutation. ͷͻ͵
 ͷͻͶ
Figure 5. Neutral evolution and tumor phylogeny. After the accumulation of ͷͻͷ
genomic alterations, the cancer expansion is likely triggered by a single critical ͷͻ͸
genomic event (the accumulation of a “full house” of genomic changes) followed ͷͻ͹
by neutral evolution that generates a large number of new mutations in ever-ͷͻͺ
smaller subclones. While the tumor heterogeneity rapidly increases, the allele ͷͻͻ
frequency of heterogeneous mutations decreases. In this context, the ͸ͲͲ
accumulation of mutations M(f) follows a characteristic 1/f distribution. Moreover, ͸Ͳͳ
the tumor phylogeny displays a characteristic fractal topology that is self-similar. ͸Ͳʹ
Sampling in different regions of the phylogenetic tree exposes distinct mutations ͸Ͳ͵
that however show the same 1/f distribution. Clonal mutations in a sample (not ͸ͲͶ
considered in the model) arose in to the most recent common ancestor of the ͸Ͳͷ
sampled cells. Due to the large population of cells sampled using bulk ͸Ͳ͸
sequencing, the overwhelming majority of detected clonal mutations belongs to ͸Ͳ͹
the trunk of the tree and therefore is found in the first cancer cell. Deviations from ͸Ͳͺ
the 1/f law indicate different dynamics from neutral growth. ͸Ͳͻ
Online Methods ͸ͳͲ
͸ͳͳ
Data analysis͸ͳʹ
The processing of exome-sequencing data from1 and TCGA2 involved ͸ͳ͵
variant calling on matched-normal pairs using Mutect3. A mutation was ͸ͳͶ
considered if the depth of coverage was 10 and at least 3 reads supported the ͸ͳͷ
variant. Mutations that aligned to a more than one genomic location were ͸ͳ͸
discarded. The WGS gastric cancers4 were processed using VarScan25, with ͸ͳ͹
minimum depth of coverage for a mutation being 10x and at least 3 reads ͸ͳͺ
supporting the variant. Non-CRCs in the TCGA had mutations called using ͸ͳͻ
Mutect according to the pipeline described in ref6. Microsatellite instability in the ͸ʹͲ
TCGA colon cancer samples was called using MSIsensor7. Annotation was ͸ʹͳ
performed with ANNOVAR8. ͸ʹʹ
To fit the neutral model to allele frequency data we considered only ͸ʹ͵
variants with allele frequency in the range [fmax,fmin] corresponding to [t0,t] in ͸ʹͶ
equation [2]. The low boundary fmin reflects the limit for the reliable detectability of ͸ʹͷ
low-frequency mutations in NGS data, which is in the order of 10%3. The high ͸ʹ͸
boundary fmax is necessary to filter out public mutations that were present in the ͸ʹ͹
first transformed cell. In the case of diploid tumors, clonal mutations are expected ͸ʹͺ
at fmax=0.5 (mutations with 50% allelic frequency are heterozygous public or ͸ʹͻ
clonal), in the case of triploid tumors, this threshold drops to 0.33 and in the case ͸͵Ͳ
of tetraploid neoplasms, it drops to 0.25. For all samples we used a boundary of ͸͵ͳ
[0.12-0.24] to account only for reliably called subclonal mutations and tumor ͸͵ʹ
purity in the samples. All the samples considered in this study were reported to ͸͵͵
have tumor purity 70% and a minimum of 12 reliably called private mutations ͸͵Ͷ
within the fit boundary. Once these conditions were met in a sample, equation [7] ͸͵ͷ
was used to perform the fit as illustrated in Figure 1B and 2B. In particular, for ͸͵͸
x=1/f, equation [7] becomes a linear model with slope ȝ/ȕ and intercept –ȝ/(ȕ ͸͵͹
fmax). We exploited the intercept constraint to perform a more restrictive fit using ͸͵ͺ
the model y=m(x-1/fmax)+0. ͸͵ͻ
 Copy-number changes (allelic deletion or duplication) can alter the ͸ͶͲ
frequency of a variant in a manner that is not described by equation [7]. We ͸Ͷͳ
assessed the impact of copy-number alterations (CNAs) on our estimates of the ͸Ͷʹ
mutation rate within the TCGA colorectal cancer samples by using the paired ͸Ͷ͵
 ͳʹ
publically available segmented SNP-array data to exclude somatic mutations that ͸ͶͶ
fell within regions of CNA. CNVs were identified having an absolute log-R-͸Ͷͷ
ratio>0.5, and the model fitting was performed only on diploid regions of the ͸Ͷ͸
genome. In the gastric cancer cohort, regions with copy number changes were ͸Ͷ͹
identified using Sequenza9 and removed from the analysis. Mutation rates were ͸Ͷͺ
adjusted to the size of the resulting diploid genome. Supplementary Figures 2 ͸Ͷͻ
and 5 demonstrate the robustness of our analysis to copy number changes. R2 ͸ͷͲ
values were independent from the mean coverage of mutations (p=0.32), the ͸ͷͳ
total number of mutations in the sample (p=0.40), the mutation rate (p=0.11), or ͸ͷʹ
the number of mutations within the model range (p=0.65). ͸ͷ͵
 ͸ͷͶ
Stochastic Simulation of Tumor Growth ͸ͷͷ
To further validate our analytical model and to test the robustness to the ͸ͷ͸
noise in NGS data, we developed a stochastic simulation of tumor growth and ͸ͷ͹
accumulation of mutations that allowed us to generate synthetic datasets. The ͸ͷͺ
model was written and analyzed in the Julia programming language.  We then ͸ͷͻ
applied the analytical model to the simulated data to confirm that sources of ͸͸Ͳ
noise in NGS data do not considerably impact our results. In particular, we ͸͸ͳ
verified that we could reliably extract input parameters of the simulation (namely ͸͸ʹ
the mutation rate) from “noisy” synthetic data. Confounding factors in the data ͸͸͵
include normal contamination, sampling effects, the detection limit of NGS ͸͸Ͷ
mutation calling, and variable read depth. We simulate a tumor using a branching ͸͸ͷ
process with discrete generations, beginning with a single “transformed” cancer ͸͸͸
cell that gives rise to the malignancy. Under exponential growth, the population at ͸͸͹
time t will be given by: ͸͸ͺ
 ͸͸ͻ
 NȋtȌ= Rt = eȋRȌt   [9] ͸͹Ͳ
 ͸͹ͳ
Where R is the average number of offspring per cell and the time ݐ is in units of ͸͹ʹ
generations. We will consider primarily the case when R=2 (a cell always divides ͸͹͵
into 2), but we will also consider values <2, noting that R must be greater than 1 ͸͹Ͷ
to have growth. At each division, cells acquire new mutations at a rate ȝ and we ͸͹ͷ
assume every new mutation is unique (infinite sites approximation). The number ͸͹͸
of mutations acquired by a newborn cell at division is a random number drawn ͸͹͹
from a Poisson distribution. Each cell in the population is defined by its mutations ͸͹ͺ
and its ancestral history (by recording it’s parent cell). Using this information we ͸͹ͻ
can then reconstruct the history of the whole tumor and crucially, calculate the ͸ͺͲ
variant allele frequency of all mutations in the population. To relate the discrete ͸ͺͳ
simulation to the continuous analytical model we will now re-derive equation [7] ͸ͺʹ
within the context of our model. As we simulate a growing tumor using discrete ͸ͺ͵
generations, both the mutation rate ȝ and per capita growth rate Ȝ=ln(R) are in ͸ͺͶ
units of generations. For an offspring probability distribution P=(p0,p1,p2) where ͸ͺͷ
pk=P(# of OFFSPRING = k) where, the average number of offspring  R is simply ͸ͺ͸
given by the expected value of P: ͸ͺ͹
 ͸ͺͺ
 R = EȏPȐ= pͳ +ʹpʹ   [10] ͸ͺͻ
 ͸ͻͲ
For example, for R=2 we have P=(p0=0,p1=0,p2=1). By choosing different ͸ͻͳ
offspring probability distributions we can easily modulate the growth rate. We ͸ͻʹ
note that we are now expressing both ȝ and Ȝ as rates per generation rather than ͸ͻ͵
probabilities (all rates are scaled by units of generation). This allows us to write ͸ͻͶ
the growth function as N(t)=exp(Ȝt) with Ȝ=ln(R). Proceeding as in the main text, ͸ͻͷ
our cumulative number of mutations with an allelic frequency f is therefore: ͸ͻ͸
 Mȋ f Ȍ= µλ
ͳ
f
−
ͳ
f
§
©¨
·
¹¸
  [11] ͸ͻ͹
Therefore, when fitting the model to our stochastic simulation we extract ȝ/Ȝ from ͸ͻͺ
the linear fit, making it straightforward to compare the simulation with the ͸ͻͻ
analytical model. ͹ͲͲ
NGS data only captures a small fraction of the variability in a tumor, as the ͹Ͳͳ
resolution is often limited to alleles with frequency >10% due to sequencing ͹Ͳʹ
 ͳ͵
depth and limitations in mutation calling. To account for this, we employ a ͹Ͳ͵
multistage sampling scheme in our simulations. For all simulations reported here ͹ͲͶ
we grow the tumor to size 1,024 cells, which gives a minimum allele frequency of ͹Ͳͷ
~0.1%, considerably smaller than the 10% attainable in next generation ͹Ͳ͸
sequencing data. After growing the tumor and calculating the VAF for all alleles, ͹Ͳ͹
we take a sample of the alleles in the population, noting that we are assuming the ͹Ͳͺ
population is well mixed and has no spatial structure. We can vary the ͹Ͳͻ
percentage of alleles we sample, thus allowing us to investigate the effect of the ͹ͳͲ
depth of sequencing on our results.  As we know the true allelic frequency in the ͹ͳͳ
simulated population, we can use the multinomial distribution to produce a ͹ͳʹ
sample of the “sequenced” alleles, where the probability of sampling allele i is ͹ͳ͵
proportional to its frequency. The probability mass function is given by: ͹ͳͶ
 ͹ͳͷ
f ȋxǢnǡpȌ= nǨ
xͳǨ  xk Ǩ
pi
xi
i=ͳ
k∏ ǡ xͳ +  xk = n                      [12] ͹ͳ͸
 ͹ͳ͹
where xi is the sampled frequency of allele i, n is the number of trials (the chosen ͹ͳͺ
percentage of alleles sampled) and pi is the probability of sampling allele i (which ͹ͳͻ
has frequency ȡi in the original population): ͹ʹͲ
pi =
ρi
ρ jj=ͳ
k¦
     [13]  ͹ʹͳ
 ͹ʹʹ
The variant allele frequency VAF is therefore given by: ͹ʹ͵
VAF =
xi
Ni
      [14] ͹ʹͶ
 ͹ʹͷ
Where Ni is the total number of sampled cells from which every sampled allele is ͹ʹ͸
derived. As we are assuming a constant mutation rate ȝ, we can assume that the ͹ʹ͹
percentage of alleles sampled comes from an equivalent percentage of cells. ͹ʹͺ
However, to include an additional element of noise that resembles the variability ͹ʹͻ
of read depth, we calculate a new Ni for each allele i, which approximates the ͹͵Ͳ
read depth.   For a desired “sequencing” depth D we calculate the corresponding ͹͵ͳ
percentage of the population we need to sample that will give us our desired ͹͵ʹ
depth. For example, for a desired depth of 100X from a population of 1,000 cells, ͹͵͵
we would need to sample 10% of the population. To include some variability in ͹͵Ͷ
depth across all alleles we use Binomial sampling so that Ni is a distribution with ͹͵ͷ
mean D.  ͹͵͸
Contamination from non-tumor cells in NGS results in variant allele ͹͵͹
frequencies being underestimated. To include this effect in our simulation we can ͹͵ͺ
modify our Ni by an additional fraction İ, the percentage of normal contamination. ͹͵ͻ
Our VAF calculation thus becomes: ͹ͶͲ
VAF =
xi
Ni ͳ+ ε( )        ͹Ͷͳ
 ͹Ͷʹ
 ͹Ͷ͵
We also include detection limit in our sampling scheme, we only include alleles ͹ͶͶ
that have an allelic frequency greater than a specified limit in the original tumor ͹Ͷͷ
population. ͹Ͷ͸
 ͹Ͷ͹
To include the effects of selection in the simulation we introduce a second ͹Ͷͺ
population, where on average each cell has a greater number of offspring than ͹Ͷͻ
the first population. To model this, our second population has a modified offspring ͹ͷͲ
probability distribution: the previous offspring probability distribution was ͹ͷͳ
P=(p0,p1,p2), and the offspring probability distribution of our second fitter ͹ͷʹ
population is defined as Q=(q0,q1,q2), where q2>p2. The selective advantage of a ͹ͷ͵
population – s, will be given by the ratio of the expected number of offspring: ͹ͷͶ
ͳ+ s = EȏQȐ
EȏPȐ
=
qͳ +ʹqʹ
pͳ +ʹpʹ
      ͹ͷͷ
 ͳͶ

Therefore given P, and a desired selective advantage s we can easily calculate ͹ͷ͸
the offspring probability distribution of a fitter clone – Q.  ͹ͷ͹
 ͹ͷͺ
Previous studies have detected the presence of mixtures of subclones in breast ͹ͷͻ
cancer samples that emerged by means of clonal expansions, thus generating ͹͸Ͳ
multiple subclonal clusters in the data10. We also used our computational model ͹͸ͳ
of NGS data to produce similar synthetic data by means of mixing of different ͹͸ʹ
clonal clusters and verified that in this scenario (a model of differential selective ͹͸͵
pressure across subclones), the power law does not hold. ͹͸Ͷ
 ͹͸ͷ
Simulation Results ͹͸͸
From the simulated data we produced histograms of the allelic frequency ͹͸͹
and calculated M(f) in order to fit the analytical model. We used the same ͹͸ͺ
frequency range as applied to empirical data [fmax,fmin]=[0.12,0.24]. ͹͸ͻ
Supplementary Figure 9A and B shows equivalent plots to Figures 1A and B but ͹͹Ͳ
with simulated data. These demonstrate that we are able to accurately model the ͹͹ͳ
allelic distribution of NGS data with our simple neutral model of tumor growth. We ͹͹ʹ
also show the effect of a low mutation rate (Supplementary Figure 9C), a large ͹͹͵
number of clonal mutations (Supplementary Figure 9D), 30% contamination in ͹͹Ͷ
the sample (Supplementary Figure 9E) and a low detection limit (Supplementary ͹͹ͷ
Figure 9F). Importantly, by fitting the analytical model to the simulated data, we ͹͹͸
can recover the input mutation rate with high accuracy (Supplementary Figure ͹͹͹
9G, 10,000 equivalent simulations). The mean percentage error from the fit is ͹͹ͺ
1.1%. We also see uniformly high R2 values across all simulations ͹͹ͻ
(Supplementary Figure 9H).  ͹ͺͲ
To test the robustness of the model to the number of clonal mutations, the ͹ͺͳ
detection limit and the amount of normal contamination we ran 10,000 ͹ͺʹ
simulations across the spectrum of these parameters. Supplementary Figures ͹ͺ͵
10A-B show that we accurately recover (to within 15%) the mutation rate for 95% ͹ͺͶ
of simulations across different numbers of clonal mutations and different ͹ͺͷ
detection limits. Differently, we found that levels of normal contamination above ͹ͺ͸
30% considerably impact the parameter estimations of the model, hence our ͹ͺ͹
decision of only considering samples with 70% of tumor content  ͹ͺͺ
(Supplementary Figure 10C). Indeed, when normal contamination is above 30%, ͹ͺͻ
the clonal peak in the allelic frequency distribution interferes significantly with our ͹ͻͲ
chosen cumulative sum limit (fmax = 0.24), thus impacting our results. ͹ͻͳ
Nevertheless, the estimates are within a factor 2 for normal contamination of up ͹ͻʹ
to 50%, which we consider an acceptable level of accuracy. When we consider ͹ͻ͵
normal contaminationߝ directly within our analytical model, the allelic fraction of a ͹ͻͶ
new mutation becomes: ͹ͻͷ
 ͹ͻ͸
f = ͳ
πNȋtȌ
=
ͳ
πeλβtȋͳ+ ε Ȍ
     [15] ͹ͻ͹
 ͹ͻͺ
And consequently, M(f) is: ͹ͻͻ
 ͺͲͲ
Mȋ f Ȍ= µβȋͳ+ε Ȍ
ͳ
f
−
ͳ
f
§
©¨
·
¹¸
     [16] ͺͲͳ
 ͺͲʹ
Showing that normal contamination alters the measurement of mutation by a ͺͲ͵
factor of 1/(1+İ): much lower than one order of magnitude. Furthermore, if normal ͺͲͶ
contamination can be estimated accurately from histopathological scoring or from ͺͲͷ
reliable bioinformatics tools, we would be able to correct the frequency of variants ͺͲ͸
in the data and thus rescue our ability to correctly estimate parameters with up to ͺͲ͹
40-45% normal contamination (Supplementary Figure 10D). We also tested the ͺͲͺ
model with varying read depths and mutation rates. We find that either a low ͺͲͻ
mutation rate or low read depth resulted in a higher proportion of poor model fits ͺͳͲ
(R2<0.98) and inaccurate or higher variance in mutation estimates ͺͳͳ
(Supplementary Figures 10E-H). It is therefore possible that due to our stringent ͺͳʹ
neutrality criteria that the true proportion of tumors that are dominated by neutral ͺͳ͵
 ͳͷ
dynamics is higher than reported, and relatedly our gastric cancer cohort covers ͺͳͶ
the whole genome (greater mutation rate per division) and has mean depth of ͺͳͷ
coverage >90X which may explain in part why we see a greater proportion of ͺͳ͸
gastric cancers classified as neutral.   ͺͳ͹
Additionally, we tested the model with simulations using a range of ͺͳͺ
different probability distributions for the number of surviving offspring at each cell ͺͳͻ
division. We simulated a growing tumor 10,000 times with 5 different offspring ͺʹͲ
probability distributions and then reported the distributions of the fitted ͺʹͳ
parameters. Supplementary Figures 10I-J show that as Ȝ decreases the ͺʹʹ
distribution of mutation estimates becomes wider and we see an increase in ͺʹ͵
poorly fitted models (larger number of R2<0.98). Again this suggests that tumor ͺʹͶ
growth may still be neutral even when we classify a tumor as non-neutral due to ͺʹͷ
a poor R2 value. Hence our underestimation of the number of neutral cases may ͺʹ͸
be largely due to a low proportion of cells that successfully produce 2 viable ͺʹ͹
offspring (the ȕ term in equation [7]), rather than the presence of selection. ͺʹͺ
By introducing a second fitter population early during tumor growth we ͺʹͻ
show that the fitter clone causes an overrepresentation of variants at high ͺ͵Ͳ
frequency compared to what we would expect from our “null” model of neutral ͺ͵ͳ
tumor growth. This causes the cumulative distribution to bend and deviate from ͺ͵ʹ
the linear relationship predicted by neutral growth, as shown in Supplementary ͺ͵͵
Figures 11A-B. This is because an overrepresentation of variants at high ͺ͵Ͷ
frequency, as compared to what we would expect from our “null” model, is ͺ͵ͷ
caused by the clonal selection of the fitter clone, but we note that we do not know ͺ͵͸
what caused this increase (it could be a point mutation, chromosomal aberration ͺ͵͹
or a change in environmental pressures for example). In other words, some ͺ͵ͺ
passenger mutations are just in the “right clone at the right time” and become ͺ͵ͻ
overrepresented in the tumour when that “right” clone expands. ͺͶͲ
We also show that having multiple subclones that arose by means of ͺͶͳ
clonal expansion, thus producing multiple clonal ‘clusters’, produces a deviation ͺͶʹ
from the linear relationship we predict (Supplementary Figures 11C-F), as does ͺͶ͵
having a marked increase in the mutation rate early in tumour growth ͺͶͶ
(Supplementary Figures 11G,H). ͺͶͷ
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